

EXACT CURE

www.exactcure.com

#DIGITALTWIN
#PRECISIONMEDICINE
#EHEALTH

VALUE FOR CLIENT

Run personalized pharmacokinetic/pharmacodynamic simulations to better monitor the effect of drugs on the population and reduce health-related costs.

BUSINESS CASE

A pharmaceutical company can reduce the attrition rate of new drug development or repositioning, and sell a « molecule + digital companion » package.

VALUE FOR USER

Our Digital Twin simulates the effect of drugs in the body of a patient based on her personal characteristics, to help her better use drugs.

INSIGHTS

Our technology is integrated into Vidal Sentinel. We have a partnership with Elsevier's PharmaPendium®. We won several technological prizes.

PHARMA INDUSTRY : DECREASE COSTS OF PHASE 3 CLINICAL TRIALS AND GET REAL WORLD EVIDENCE.

HEALTH INSURERS : INCREASE CUSTOMER LOYALTY AND REDUCE COSTS.

ExactCure develops a software solution to avoid medication errors.

To deliver actually personalized medicine, our Digital Twin simulates in-silico the efficacy and interactions of medicines in the body of a patient based on his/her personal characteristics.

* Pharmaceutical companies and CROs can detect outliers who do not react as expected during clinical trials for new drug development or drug repurposing before they jeopardize the whole trial. They can also differentiate and get Real World Evidence for marketed drugs by selling a « molecule + digital companion » package.

* Hospitals, clinics and healthcare professionals can run personalized simulations to adapt posologies to each patient.

* Health insurance companies, HMOs and large employers can reduce costs, and be considered as a trusted third party in healthcare.

VALUE FOR BRAND

2021

GEOGRAPHIC COVERAGE

WW (CE Marked)

HQ LOCALIZATION

Nice, France

FOUNDERS

Frédéric Dayan
Sylvain Bénito
Fabien Astic

FUNDINGS

1,7M€ incl. 700k€ in equity.

INVESTORS

OneRagtime